Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Dysregulation of a long noncoding RNA reduces leptin leading to a leptin-responsive form of obesity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Peripheral memory T cells specific for Arginase-1

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Real-world evidence to guide healthcare policies in oncology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. undersøges !!

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Paolo Antonio Ascierto
  • Pier Francesco Ferrucci
  • Rosalie Fisher
  • Michele Del Vecchio
  • Victoria Atkinson
  • Henrik Schmidt
  • Jacob Schachter
  • Paola Queirolo
  • Georgina V Long
  • Anna Maria Di Giacomo
  • Inge Marie Svane
  • Michal Lotem
  • Gil Bar-Sela
  • Felix Couture
  • Bijoyesh Mookerjee
  • Razi Ghori
  • Nageatte Ibrahim
  • Blanca Homet Moreno
  • Antoni Ribas
Vis graf over relationer

Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses that are induced by the combined inhibition of BRAF and MEK1. Here we performed a randomized phase 2 trial ( NCT02130466 ), in which patients with treatment-naive BRAFV600E/K-mutant, advanced melanoma received the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib together with the PD-1-blocking antibody pembrolizumab (triplet; n = 60) or placebo (doublet; n = 60). The primary end point of progression-free survival was numerically improved in the triplet group-16.0 months-compared with 10.3 months in the doublet group (hazard ratio, 0.66; P = 0.043); however, the trial did not reach the planned benefit for a statistically significant improvement. Median duration of response was 18.7 months (95% confidence interval, 10.1-22.1) and 12.5 months (95% confidence interval, 6.0-14.1); 59.8 and 27.8% of responses were estimated to have lasted for more than 18 months for triplet and doublet treatment, respectively. Grade 3-5 treatment-related adverse events occurred in 58.3 and 26.7% of patients treated with triplet and doublet therapies, respectively, which were most commonly fever, increased transaminase levels and rash. One patient who received triplet therapy died of pneumonitis. In summary, triplet therapy with dabrafenib, trametinib and pembrolizumab conferred numerically longer progression-free survival and duration of response with a higher rate of grade 3/4 adverse events compared with the doublet therapy of dabrafenib, trametinib and placebo.

OriginalsprogEngelsk
TidsskriftNature Medicine
Vol/bind25
Udgave nummer6
Sider (fra-til)941-946
Antal sider6
ISSN1078-8956
DOI
StatusUdgivet - jun. 2019

ID: 57729068